Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
18.58
-1.10 (-5.59%)
At close: Jun 5, 2026, 4:00 PM EDT
18.95
+0.37 (1.99%)
After-hours: Jun 5, 2026, 5:47 PM EDT
Immunome Revenue
Immunome had revenue of $4.01M in the twelve months ending March 31, 2026, down -63.29% year-over-year. In the year 2025, Immunome had annual revenue of $6.94M, down -23.23%.
Revenue (ttm)
$4.01M
Revenue Growth
-63.29%
P/S Ratio
524.08
Revenue / Employee
$19,490
Employees
206
Market Cap
2.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.94M | -2.10M | -23.23% |
| Dec 31, 2024 | 9.04M | -4.98M | -35.50% |
| Dec 31, 2023 | 14.02M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 670.00M |
| Aurinia Pharmaceuticals | 298.30M |
| Intellia Therapeutics | 66.09M |
| Nektar Therapeutics | 55.63M |
| Celldex Therapeutics | 865.00K |
IMNM News
- 3 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 days ago - Immunome announces Ringside trial met primary, secondary endpoints - TheFly
- 8 days ago - Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - Business Wire
- 9 days ago - Immunome Slides: Investor presentation - Filings
- 10 days ago - Immunome price target raised to $37 from $36 at Truist - TheFly
- 10 days ago - Immunome initiated with an Overweight at Barclays - TheFly
- 11 days ago - Immunome to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - Business Wire
- 23 days ago - Immunome price target lowered to $33 from $37 at Leerink - TheFly